Trial Profile
An Open-Label Phase II Study of Nivolumab in Adult Participants With Progressive/Recurrent Meningioma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 23 Jan 2024 Planned End Date changed from 1 Jun 2024 to 1 Sep 2025.
- 23 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Mar 2025.
- 09 Jan 2023 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.